Press release

The MED-EU strategic project aims to raise EU funds for scientific research and innovation. The project is coordinated by the University of Bologna and a few clinical institutes such as the S.Orsola-Malpighi University Hospital, the Rizzoli Institute for Orthopedics and the Institute for Neurologic Sciences of the Bellaria hospital.

Dr. Gilbert Lenssen, ABIS' Founding President: "I am confident that Sauquet will lead the network with great strength and support from its members"

Fluidic Analytics Limited, a spinout from the University of Cambridge, has raised £1.56 million (US$2.4 million) in a Series A financing led by Cambridge Enterprise and including DFJ Esprit, IQ Capital, Parkwalk Advisors and Amadeus Capital Partners as co-investors.

ESADE will develop educational offerings specifically designed to strengthen the executive and leadership skills of digital entrepreneurs

A new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. The drug, Lynparza, has been granted Marketing Authorisation from the European Commission.

Imperial has the greatest concentration of high impact research of any major UK university, according to the Research Excellence Framework (REF) 2014.

A total of 22 new companies were founded in 2014 by researchers from ETH Zurich. These spin-offs are among the most successful in Switzerland. One of the year's highlights was Covagen, which was acquired for over CHF 200 million. The latest figures also reveal that the university is on the right track with its promotion programmes.

Researchers at University of Bologna designed the first self-assembling molecular motor capable of converting light energy into work. The study was published in Nature Nanotechnology.

Special emphasis was put on good usability in the selection process of the new research information management system.